Thousands of men will soon have access to a life-prolonging prostate cancer medication through the NHS. Patients with localized cancer will be able to receive abiraterone in England shortly as the health service expands its treatment options. About 2,000 individuals diagnosed in the past three months will qualify for the drug initially, with an estimated 7,000 men eligible each year.
Abiraterone, an oral prescription tablet, halts cancer progression by depriving the disease of necessary hormones for growth. NHS studies indicate that the survival rate after six years on abiraterone was 86%, surpassing the 77% rate for standard treatment.
Prostate cancer is the most prevalent cancer among men and the second most common overall in the UK, with over 55,000 new cases annually. Following Cancer Research UK data, NHS England has approved the drug for a larger pool of eligible patients.
Health and Social Care Secretary Wes Streeting emphasized the government’s dedication to combatting prostate cancer. He highlighted the importance of evidence-based decisions and timely care provision to enhance outcomes and quality of life for patients.
Professor Peter Johnson, National Clinical Director for Cancer at NHS England, noted the potential life-changing impact of abiraterone for thousands of men with prostate cancer. The treatment’s imminent availability will offer hope for extended survival and improved health for many patients.
In a related development, researchers at the University of Cambridge are developing a groundbreaking blood test to detect prostate cancer accurately. The innovative test examines DNA methylation markers released by tumors, providing insights into cancer presence and severity without invasive biopsy procedures.
Men with elevated PSA levels from previous tests may benefit from this new blood test, which promises a non-invasive and efficient approach to determine the need for further treatment.